A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak płuca w stadiu I-III potwierdzony w chwili diagnozy
- •Wiek co najmniej 18 lat w momencie diagnozy raka płuca
- •Diagnoza postawiona między majem a grudniem 2025, 2026 lub 2027
✗ Disqualifies
- •Rak płuca nie jest głównym nowotworem u pacjenta
- •Historia lub obecność innego nowotworu w czasie diagnozy
- •Uczestnictwo w innym badaniu klinicznym w momencie diagnozy
- •Ciąża potwierdzona w chwili diagnozy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Locations (1)
Research Site
Beijing, China
Trial contact
AstraZeneca Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.